Human Proteome Arrays for Auto-Antibody Identification in Clinical Cancer Studies
Department of Health and Human Services
Agency Tracking Number:
Solicitation Topic Code:
Small Business Information
MESO SCALE DIAGNOSTICS, LLC
MESO SCALE DIAGNOSTICS, LLC, 9238 GAITHER RD, GAITHERSBURG, MD, 20877
Socially and Economically Disadvantaged:
AbstractDESCRIPTION (provided by applicant): Human Proteome Arrays for Auto-Antibody Identification in Clinical Cancer Studies The goal of this project is to develop protein arrays on a proteome scale for high throughput discovery and validation of cancer-specific autoantibody signatures. Early detection of cancer is a critical factor for the successful treatment of cancer patients. The discovery of specific autoantibody signatures in cancer patients has led to the recognition that autoantibody responses may have d iagnostic potential. The lack of high throughput methods for rapidly screening and validating multiple antigens of interest has been identified as an important bottleneck for the development of autoantibodies as biomarkers for cancer diagnosis. We will tes t normal and cancer patient sera against protein arrays generated using a gene library expressing human full-length proteins. Autoantibodies against the proteins in these arrays will be identified using electrochemiluminescence (ECL) detection technology, a proven technology for high throughput array-based measurements that will enable studies with large numbers of patient samples. Our approach will offer key advantages over existing array-based approaches by providing a high throughput, sensitive and speci fic assay platform. This approach will also facilitate the rapid transition from discovery of antigens using large arrays to clinical validation of the hits using small focused arrays on the same diagnostic platform. In the Phase I portion of the proposed project, we will demonstrate technical feasibility of the approach; in the Phase II portion we will develop and validate the proteome-scale arrays, and use them to screen cancer serum samples to identify a promising subset of autoantigens; the selected sub set will then be further tested with a large number of individual samples.
* information listed above is at the time of submission.